Advanced glycation end product receptor-mediated cellular dysfunction

Area of Science:

• Biochemistry
• Immunology
• Pathophysiology

Background:

• Advanced glycation end products (AGEs), S100/calgranulins, and HMGB1 proteins are implicated in chronic inflammatory diseases like diabetes mellitus.
• These molecules promote cellular dysfunction by binding to cell surface receptors, notably the receptor for AGEs (RAGE).
• RAGE engagement converts transient cellular activation into sustained dysfunction, a key mechanism in chronic diseases.

Purpose of the Study:

• To investigate the role of RAGE and its ligands in chronic inflammation and cellular dysfunction.
• To compare the protective effects of soluble RAGE (sRAGE) against RAGE deficiency in disease models.
• To explore potential alternative receptor pathways activated by abundant RAGE ligands.

Main Methods:

• Utilizing animal models, including RAGE knockout (RAGE-/-) mice.
• Administering soluble RAGE (sRAGE) to block ligand-RAGE interactions.
• Assessing cellular activation, dysfunction, and immune responses in different experimental settings.

Main Results:

• Blockade of ligand-RAGE interaction with sRAGE effectively suppresses chronic cellular activation and dysfunction in animal models.
• RAGE-/- mice exhibit less protection compared to sRAGE treatment, indicating sRAGE's broader impact.
• sRAGE can protect RAGE-/- mice in specific adaptive immune response contexts, suggesting RAGE-independent mechanisms.

Conclusions:

• While RAGE is central to chronic inflammation, its ligands may also activate other receptors.
• sRAGE demonstrates significant therapeutic potential beyond simply blocking RAGE, possibly by interacting with other pathways.
• Further research is needed to identify these alternative receptors and their roles in RAGE-mediated diseases.